Treating Diarrhea in Transplant Patients, AIDS Patients, and Children

SLU ID 20-003 | Arylacetamide Analogs of Piperazine-[1,2,4]triazolo[4,3-b]pyridazines

Background

Cryptosporidium is a microscopic parasite responsible for the diarrheal disease cryptosporidiosis, which causes life-threatening diarrhea in infants worldwide and incurable diarrhea in AIDS and transplant patients. It is the most common cause of waterborne diarrheal outbreaks in the United States and Europe. There is a need for new and more effective drugs than what is currently available on the market.

Overview

Researchers at Saint Louis Univeristy have discovered novel compounds that have demonstrated submicromolar potency against Cryptosporidium Parvym during in vitro testing. These compounds have the potential to be utilized as drugs to treat cryptosporidiosis and may be more effective than current market offerings.

Benefits

The potential benefits of this technology include:

• increasing effectiveness of treatment for cryptosporidiosis

• minimizing patient recovery time in the hospital

• increasing the quality of life for patients

• minimizing infant mortality caused by cryptosporidiosis

Applications

This technology has potential application in the following:

• Addressing diseases suffered by malnourished children worldwide

• Treating immuno-compromised patients

Opportunity

Saint Louis University is seeking partners to further develop and commercialize this technology.